Evidence map›Paper›PMID 28467776›Full record

ArticleOncotarget2017

HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.

Jiahui An, Jie Xu, Jiao Li, Song Jia, Xiaonan Li, Yanan Lu, Yuxin Yang, Zhuojia Lin, Xiaoru Xin, Mengying Wu and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. HPV11 targeting KDM4A regulates the polarization of macrophage MCell communication and signaling : CCS · 2024
    Article
  4. Review
  5. Super-enhancers complexes zoom in transcription in cancer.Journal of experimental & clinical cancer research : CR · 2023
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Jiahui AnSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Jie XuSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Jiao LiSchool of Medicine, Tongji University, Shanghai, 200092, China.
Song JiaSchool of Medicine, Tongji University, Shanghai, 200092, China.
Xiaonan LiSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Yanan LuSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Yuxin YangSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Zhuojia LinSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Xiaoru XinSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Mengying WuSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Qidi ZhengSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Hu PuSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Xin GuiSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Tianming LiSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Dongdong LuSchool of Life Science and Technology, Tongji University, Shanghai, 20092, China.
Tongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes in histone lysine methylation status have been observed during cancer formation. JMJD2A protein is a demethylase that is overexpressed in several tumors. Herein, our results demonstrate that JMJD2A accelerates malignant progression of liver cancer cells in vitro and in vivo. Mechanistically, JMJD2A promoted the expression and mature of pre-miR372 epigenetically. Notably, miR372 blocks the editing of 13th exon-introns-14th exon and forms a novel transcript( JMJD2AΔ) of JMJD2A. In particular, JMJD2A inhibited P21(WAF1/Cip1) expression by decreasing H3K9me3 dependent on JMJD2AΔ. Thereby, JMJD2A could enhance Pim1 transcription by suppressing P21(WAF1/Cip1). Furthermore, through increasing the expression of Pim1, JMJD2A could facilitate the interaction among pRB, CDK2 and CyclinE which prompts the transcription and translation of oncogenic C-myc. Strikingly, JMJD2A may trigger the demethylation of Pim1. On the other hand, Pim1 knockdown and P21(WAF1/Cip1) overexpression fully abrogated the oncogenic function of JMJD2A. Our observations suggest that JMJD2A promotes liver cancer cell cycle progress through JMJD2A-miR372-JMJD2AΔ-P21WAF1/Cip1-Pim1-pRB-CDK2-CyclinE-C-myc axis. This study elucidates a novel mechanism for JMJD2A in liver cancer cells and suggests that JMJD2A can be used as a novel therapeutic targets of liver cancer.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell CycleCell Line, TumorCell ProliferationCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p21Disease Models, AnimalEpigenesis, GeneticFungal ProteinsHeterograftsHumansJumonji Domain-Containing Histone DemethylasesLiver NeoplasmsMaleMiceCyclin-Dependent Kinase 2Cyclin-Dependent Kinase Inhibitor p21Fungal ProteinsJumonji Domain-Containing Histone DemethylasesKDM4A protein, humanMicroRNAsMIRN372 microRNA, humanMitogen-Activated Protein KinasesPim1 protein, Pichia pastorisRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesHistoneH3 demethylase JMJD2Aliver cancermiR372P21WAF1/Cip1Pim1

Identifiers

PMID28467776
PMCPMC5564752
OpenAlexW2606414960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.